Status:

UNKNOWN

dTMS as a Treatment for Patients With Fibromyalgia

Lead Sponsor:

Shalvata Mental Health Center

Conditions:

Studying Efficacy of dTMS in FM

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

Purpose: The purpose of the study is to explore the efficacy of H1 deep TMS for the treatment of FMS. Design: Prospective randomized sham controlled trial Study Population \& sample size:forty (40) F...

Eligibility Criteria

Inclusion

  • Age: 18-80 years.
  • Patients who continue to take their administered medications or patients who stopped ineffective administered medications
  • Concomitant medication for pain and sleep disorders will be allowed provided the dose administered had been stable for at least 2 weeks before enrollment and remains stable throughout the study.
  • Gave informed consent for participation in the study.

Exclusion

  • Subjects will be excluded if evidence is found of inflammatory rheumatic disease, autoimmune disease, or other painful disorders that might confound assessment of FMS pain.
  • Subjects diagnosed with a current primary (Axis I) psychiatric condition according to Diagnostic and Statistical Manual of Mental Disorders-IV criteria, including anxiety disorders, not including major depression or major personality disorder. Subject with a history of substance abuse and pregnant women will be excluded as well.
  • History of any metal in the head (outside the mouth).
  • Known history of any metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, surgical clips or any medical pumps.
  • History of head injury.
  • History of seizure or heat convulsion.
  • History of epilepsy or seizure in first degree relatives.
  • History of frequent or severe headaches.
  • Use of hearing aids for hearing loss.
  • Known history of cochlear implants.
  • History of drug abuse or alcoholism during the last year.
  • Serious and unstable medical condition, which is likely to exacerbate or endanger the patient during the treatment period.
  • Significant difficulties in language or communication.
  • Subjects declared as legally incompetent, with an appointed physical guardian and/or cannot sign informed consent due to cognitive incompetence.
  • Participation in current clinical study or clinical study within 30 days prior to this study.

Key Trial Info

Start Date :

April 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2020

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT03460340

Start Date

April 1 2018

End Date

April 1 2020

Last Update

March 9 2018

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.